Myriad’s BRCA breast cancer genetic test “Multisite 3 BRACAnalysis” is the same test as 23andMe’s BRCA breast cancer genetic test “BRCA Cancer Mutations (Selected).” Both services test for the same mutations to produce the same diagnosis medical diagnosis justified by the same medical research.

See the exhibit above which depicts genetic test results for 23andMe’s BRCA genetic test and Myriad BRCA genetic test.

The contested 23andMe claim is published by 23andMe online at 23andMe’s Terms of Service, Section 3.

Contested 23andMe Claim

23andMe Service Is For Research and Educational Use Only. We Do Not Provide Medical Advice, And The Services Cannot Be Used For Health Ascertainment or Disease Purposes.

The objections to this claim are that this same test is already defined for use as “health ascertainment or disease purposes” and that the use of this test is already included in standard medical practices in the United States. One implementation of this test for use as “health ascertainment or disease purposes” includes the Myriad “Multisite 3 BRACAnalysis” test.

Thus, either the 23andMe “BRCA Cancer Mutations (Selected)” test is medicine, or the the Myriad “Multisite 3 BRACAnalysis” test is not medicine.

Note: The 23andMe and Myriad reports depicted in this exhibit have been reformatted for publication on the Internet. Email me if you would like an unformatted copy of either report depicted in the display.